Home > Rheumatology > EULAR 2020 > Rheumatoid Arthritis > New nanoparticle promising future agent in RA

New nanoparticle promising future agent in RA

Presented By
Prof. Kira Astakhova, Technical University of Denmark, Denmark
EULAR 2020
A first-in-class therapeutic nanoparticle drug for the specific targeting of anti-citrullinated protein antibodies (ACPAs) has been developed, which may be a promising new therapeutic option for patients with rheumatoid arthritis (RA) [1]. “Several in vitro studies have suggested a pathogenic role of ACPAs in RA,” according to Prof. Kira Astakhova (Technical University of Denmark, Denmark) who presented the late-breaking abstract. The authors hypothesised that reducing ACPA levels would have a therapeutic effect by blocking cytokine production. Thus, a series of therapeutic nanoparticles for specific targeting of ACPA in synovial fluid was prepared and tested. Nanoparticles were prepared by the microdroplet method and then decorated with synthetic cyclic citrullinated peptide aptamer PEP2, PEG/hexanoic acid, and fluorophore (Cy5.5). Nanoparticles were used in a series of in vitro assays and in vivo studies including disea...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on